Table 2. Association between clinical characteristics and laboratory-confirmed monkeypox (MPX) or varicella (VZV) case classification.
| Sign or Symptom | All suspect cases (752) | Laboratory-confirmed MPX cases (333) | Laboratory-confirmed VZV cases (383) | p-valuea | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| nb | Nb | % | n | N | % | n | N | % | ||
| Fever | 732 | 737 | 99.3% | 329 | 329 | 100% | 371 | 376 | 98.7% | 0.0644 |
| Rash | 718 | 750 | 95.7% | 316 | 332 | 95.2% | 367 | 382 | 96.1% | 0.5594 |
| Febrile Prodrome | 727 | 741 | 98.1% | 327 | 330 | 99.1% | 371 | 379 | 97.9% | 0.1965 |
| Nausea | 140 | 737 | 19.0% | 75 | 328 | 22.9% | 58 | 374 | 15.5% | 0.0131 |
| Cough | 347 | 744 | 46.6% | 192 | 331 | 58.0% | 135 | 378 | 35.7% | <0.0001 |
| Lymphadenopathy | 562 | 731 | 76.9% | 277 | 325 | 85.2% | 265 | 371 | 71.4% | <0.0001 |
| Axillary | 369 | 737 | 50.1% | 191 | 327 | 58.4% | 166 | 375 | 44.3% | 0.0002 |
| Cervical | 416 | 736 | 56.5% | 206 | 326 | 63.2% | 195 | 375 | 52.0% | 0.0028 |
| Inguinal | 323 | 738 | 43.8% | 168 | 326 | 51.5% | 142 | 377 | 37.7% | 0.0002 |
| Chills | 593 | 744 | 79.7% | 262 | 328 | 79.9% | 302 | 381 | 79.3% | 0.8400 |
| Mouth ulcers | 333 | 741 | 44.9% | 190 | 326 | 58.3% | 131 | 381 | 34.4% | <0.0001 |
| Sore Throat | 451 | 738 | 61.1% | 246 | 325 | 75.7% | 188 | 378 | 49.7% | <0.0001 |
| Headache | 548 | 729 | 75.2% | 243 | 322 | 75.5% | 283 | 373 | 75.9% | 0.9011 |
| Pruritis | 379 | 734 | 51.6% | 170 | 321 | 53.0% | 196 | 378 | 51.9% | 0.7701 |
| Malaise | 453 | 720 | 62.9% | 228 | 319 | 71.5% | 211 | 367 | 57.5% | 0.0001 |
| Fatigue | 590 | 740 | 79.7% | 278 | 328 | 84.8% | 286 | 377 | 75.9% | 0.0032 |
| Conjunctivitis | 126 | 739 | 17.1% | 79 | 328 | 24.1% | 43 | 377 | 11.4% | <0.0001 |
| Sensitivity to light | 198 | 729 | 27.2% | 105 | 323 | 32.5% | 86 | 372 | 23.1% | 0.0057 |
| Bedridden | 137 | 743 | 18.4% | 95 | 327 | 29.1% | 41 | 381 | 10.8% | <0.0001 |
| Rash characteristics | ||||||||||
| Monomorphic | 573 | 658 | 87.1% | 286 | 319 | 89.7% | 264 | 312 | 84.6% | 0.0585 |
| Same size | 581 | 657 | 88.4% | 291 | 319 | 91.2% | 264 | 311 | 84.9% | 0.0063 |
| Deep-seated and firm | 621 | 660 | 94.1% | 310 | 319 | 97.2% | 286 | 314 | 91.1% | 0.0011 |
| Rash site | ||||||||||
| Face | 736 | 743 | 99.1% | 330 | 333 | 99.1% | 372 | 375 | 99.2% | 0.8838 |
| Thorax | 723 | 743 | 97.3% | 328 | 333 | 98.5% | 362 | 375 | 96.5% | 0.0973 |
| Arms | 704 | 742 | 94.9% | 326 | 332 | 98.2% | 345 | 375 | 92.0% | 0.0002 |
| Legs | 331 | 352 | 94.0% | 191 | 197 | 97.0% | 125 | 138 | 90.6% | 0.013 |
| Palms | 677 | 742 | 91.2% | 324 | 333 | 97.3% | 319 | 374 | 85.3% | <0.0001 |
| Soles | 604 | 743 | 81.3% | 309 | 333 | 92.8% | 264 | 375 | 70.4% | <0.0001 |
| Genitals | 144 | 692 | 20.8% | 87 | 309 | 28.2% | 52 | 349 | 14.9% | <0.0001 |
a Chi-square test between laboratory-confirmed MPX and VZV cases. Significant p-values (p<0.05) are in bold.
b n is the number of cases reported to have the sign/symptom and N is the total number of cases with data present.